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Abstract
Chlorpromazine is a sedative effective 
phenothiazine derivative used to prevent 
nausea and vomiting, especially in cases of 
motion sickness in cats. It has serious side 
effects at high doses, including weakness, 
tremors, loss of anal sphincter tone and 
reflexes, hypotension, heart rhythm 
abnormalities, coma, agitation and seizures. 
In this case report, chlorpromazine toxicity 
was defined in a 4-month-old, 1.2 kg male 
Van kitten brought to Selcuk University 
Veterinary Faculty Emergency Clinic with 
complaints of stagnation, tremors, vomiting 
and excessive sleepiness. Hypothermia 
(35.2 °C), hyperpnea (88 breaths/min), 
hypersalivation, constipation, excessive 
agitation, tremors and incoordination were 
determined in the clinical examination of the 
kitten. It was learned from the anamnesis 
that 100 mg chlorpromazine was given orally 
before the trip against motion sickness. 
Electrocardiographic examination determined 
sinus tachycardia (220 beats/min), increase in 
P wave amplitude, elevation in ST complex 
and hypotension (S/MAP/D = 148/124/112). 
The major laboratory findings were metabolic 
acidosis (pH 7.278), hypoglycaemia (61 mg/
dL), leukocytosis (22.43 m/mm3), increase in 
blood ured nitrogen (17.7 mg/dL), creatinine 
(0.6 mg/dL) and ALP (121 U/L) concentrations 
and hypertriglyceridemia (122 mg/dL). 
Based on the anamnesis, clinical, laboratory 
and ECG findings, the kitten was diagnosed 
with overdose chlorpromazine toxicity and 
hospitalized, and put under surveillance for 
continuous cardiac monitoring. Lactated 
ringer solution, norepinephrine tartrate, 
furosemide, activated charcoal and oxygen 
therapy were given. The treatment was 
successful. In conclusion, it was evaluated 
that continuous cardiac monitoring and 
controlling hypotension were important in the 
management of chlorpromazine toxicity, and 
fluid therapy, norepinephrine, diuretic and 
activated charcoal administrations achieve 
success in treatment.
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Introduction
Chlorpromazine hydrochloride (CPH) 
is an antipsychotic neuroleptic drug main-
ly used in the treatment of neurological dis-
orders. CPH is effective on all layers of the 
central nervous system, especially at the 
subcortical level. It has strong antiadren-
ergic and weak peripheral anticholinergic 
activity. Ganglionic blockade is relatively 
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weak. In addition, it has mild antihista-
minic, antiseratonergic, sedative, hypoten-
sive and antiemetic activities. The antipsy-
chotic activity of CPH is associated with 
blockage of D2 dopamine receptors in the 
brain (Haddad and Winchester, 1990). At 
high doses, CPH can completely block D2 
dopamine receptors and seriously impair 
the neurotransmission of nigrostrial, mes-
olimbic, mesocortical dopaminergic path-
ways, hypothalamic dopamine neurons, 
and peripheral dopaminergic areas (Pois-
index, 2006). CPH is commonly metabo-
lised in the liver and excreted through the 
kidneys (Li et al., 2008). The metabolism 
pathway is cytochrome P450 isoenzyme 
CYP2D6, CYP1A2 and CYP3A4. Approx-
imately 10-12 metabolites have been iden-
tified in this pathway. N-oxide occurs by 
hydroxylation at positions 3 and 7 of the 
phenothiazine nucleus and demethylation 
of the N-dimethylaminpropyl side chain. 
20% of CPH and its metabolites are excret-
ed in the urine in unconjugated form. The 
remaining 80% are conjugated metabo-
lites (Leucht et al., 2003). CPH causes hy-
potension with alpha adrenergic blockade 
(Trepanier, 2010). It has also been reported 
to cause an increase in serum glucose and 
cholesterol levels, and blockages in the so-
dium, calcium and potassium channels (Li 
et al., 2008; FDA Label, 2017). 
Chlorpromazine is used for sedative 
purposes, especially in cats against 
motion sickness and to eliminate nausea 
and vomiting (Gollakner, 2019). It can 
be used in case of motion sickness and 
nausea (0.1-2.2 mg/kg, IV, TID), in cases 
of non-severe vomiting (0.1-2.2 mg/kg, 
PO, BID) and for sedation purposes (0.5 
mg/kg IM or IV) (Dollery and Boobis, 
1992). It is fast-acting, with clinical 
symptoms developing within 1-2 hours 
of use. At high doses, it can cause tremors, 
drowsiness, loss of reflexes and anal 
sphincter tone in cats. Coma, agitation, 
seizures, abnormal heart rhythm and 
severe hypotension are the main side 
effects (Gollakner, 2019).
Description of the Case
This case report describes the 
toxicity of chlorpromazine in a 4-month 
old male Turkish Van cat weighing 
1.2 kg. The cat was given a 100 mg 
Table 1. Blood gases, hemogram and serum 
biochemistry findings
Blood gases Reference
pH 7.27 7.35 – 7.45
Potassium mmol/L 3.8 3.4 – 5.6
Sodium mmol/L 157 150 - 165
Chlorine mmol/L 127 104 - 128
Glucose mg/dL 61 64 - 170
Lactate mmol/L 3.1 0 - 2
Base excess mmol/L -15.3 -4 - 4
HCO3 (P,st) mmol/L 11.5 19 - 24
Haematology Reference
WBC m/mm3 22.43 5.0 – 19.0
Lymphocyte m/mm3 6.68 0.2 – 5.7
Monocyte m/mm3 0.96 0.1 – 1.1
Granulocyte m/mm3 14.79 2.0 – 15.2
RBC M/mm3 6.89 4.0 – 9.0
MCV Fl 51.4 35.5 – 55.0
MCH Pg 14.2 16.0 – 24.0
MCHC g/dL 27.6 28.0 – 40.0
Serum Biochemistry Reference
BUN mg/dL 17.7 4.7-14.3
Creatinine mg/dL 0.6 0.8-1.80
ALP U/L 121 10-80.00
ALT U/L 51 10-80.00
Albumin g/dL 2.9 2.1-3.90
Triglycerides mg/dL 122 10-114.0
Cholesterol mg/dL 139 90-205.0
Total Protein g/dL 5.4 5.4-7.80
HCO3: Bicarbonate, WBC: Leukocyte, RBC: Erythrocyte, 
MCV: Mean corpuscular volume, MCH: Mean 
corpuscular haemoglobin, MCHC: Mean corpuscular 
haemoglobin concentration, BUN: Blood urea nitrogen, 
ALP: Alkaline phosphatase, ALT: Alanine transaminase.
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dose of chlorpromazine (Largactil®, 
Eczacıbaşı) orally by the owner against 
motion sickness, and within 2-3 hours 
of administration of the drug, it was 
brought to the Selcuk University, Faculty 
of Veterinary Medicine, Emergency Clinic 
with complaints of stagnation, tremor, 
vomiting, and excessive sleepiness. 
In the anamnesis of the kitten, it was 
learned that an overdose of chlorprom-
azine was given orally against motion 
sickness. On physical examination, hypo-
thermia (35.2 °C), hyperpnea (88 breaths/
min), hypersalivation, fall in nictitating 
membrane (third eyelid), constipation, 
excessive agitation, tremor and incoor-
dination were determined. Laborato-
ry analysis of blood gases (Radiometer 
ABL 90 automatic analyzer, Model 5700, 
74351, USA), haemogram (MS4 CFE 279, 
France), serum biochemistry (BT 3000 
plus, Biotecnical Inc, SPA, Rome, Italy), 
urine dipstick analysis ( URIT-50Vet, 
Guangxi, China), ECG (Edan IM8 Vet, 
standard bipolar lead system (I, II and 
III; 50 mm/second; 101 mm = 1mV) and 
echocardiography (SIUI Apogee 3500, 
right parasternal long and short axis 
Figure 1. ECG findings
Figure 2. Echocardiographic findings
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2D and M-mode) were performed. The 
blood gas analysis showed metabolic 
acidosis, severe base deficit, and hypo-
glycaemia; the haemogram analysis de-
tected leukocytosis; serum biochemistry 
showed increases in BUN, creatinine, 
ALP and triglyceride concentrations (Ta-
ble 1), while the urine dipstick analysis 
findings were normal. 
The electrocardiograph showed 
sinus tachycardia (220 bpm), increase in 
P wave amplitude and elevation in ST 
complex (Figure 1), along with normal 
echocardiograph findings (Figure 2).
In line with the anamnesis, clinical, 
laboratory and ECG findings, the kitten 
was diagnosed with overdose chlor-
promazine toxicity. The kitten was hos-
pitalized, and put under surveillance for 
continuous cardiac monitoring. To con-
trol hypothermia, the kitten was kept in a 
temperature and oxygen ratio adjustable 
incubator. Oxygen supplementation (50 
mL/kg/min) and fluid therapy (Lactated 
Ringer’s solution 60 mL/kg, IV, Polyplex, 
Polifarma®) were administrated. Norepi-
nephrine tartrate (10 µg/kg, IV, Cardenor, 
Defarma®) for control of hypotension, 
furosemide (1 mg/kg, IM, Diuril, Vetaş®) 
for diuresis and activated charcoal (1 g/
kg, PO, Dimetrol, Anadolu®) to prevent 
toxin absorption were given. The kitten 
was discharged with normal clinical and 
cardiovascular findings after 24 hours. 
According to the information received 
from the animal owner, two days after 
discharge the cat was reported to still ex-
hibit sleepiness, though seven days after 
discharge, all symptoms disappeared.
Discussion
The main side effects of CPH are 
central nervous system depression, 
such as sleepiness and coma. 
Cardiovascular toxicity of CPH results 
in ECG abnormalities such as postural 
hypertension, AV block, ventricular 
tachycardia, prolonged QT interval, 
ventricular fibrillation, or cardiac arrest 
(Haddad and Winchester, 1990). ECG 
abnormalities associated with the use 
of chlorpromazine at high doses and 
hypotension have been reported to 
be due to alpha adrenergic blockade 
(Trepanier, 2010). Based on normal 
echocardiographic examination findings, 
the cardiac abnormalities detected in this 
presented case (Figure 1) were evaluated 
to be based on alpha adrenergic blockade. 
As a result of the effect of CPH on the 
autonomic nervous system, vasodilation, 
hypotension and tachycardia developed. 
Saliva and gastric secretions were reduced. 
In early or mild toxicities, patients may 
experience restlessness, photosensitivity, 
urinary retention, agitation, akathisia, 
dystonia and confusion. Tremors due 
to dopamine antagonism, muscle tics, 
spasms, rigidity, convulsions, muscle 
hypotonia, torticollis, opistotonus and 
ocular lesions can be seen (Trepanier, 
2010). Although hyperthermia can be 
seen, hypothermia is more common 
(Nunes et al., 1996). Constipation, 
dyspnea, cyanosis, respiratory collapse, 
distress and rarely excessive antidiuretic 
hormone (ADH) release, water retention, 
liver damage, cholestatic icterus are other 
clinical symptoms (Baselt and Cravey, 
1995). In this case, clinical symptoms were 
determined as hypothermia, hyperpnea, 
hypersalivation, fall in nictitating 
membrane, constipation, excessive 
agitation, tremor and incoordination.
Overdose reports include haemato-
logical changes such as agranulocytosis, 
eosinophilia, leukopenia, haemolytic 
anaemia, aplastic anaemia, thrombocy-
topenic purpura, pancytopenia and hy-
per/hypoglycaemia and glucosuria (PIM, 
2005). In addition, high alkaline phos-
phatase (ALP) levels (Cares et al., 1957), 
hypertriglyceridemia and hyponatremia 
have been reported in serum biochemis-
try for therapeutic use of CPH and its tox-
icities (FDA Label, 2017). In the present-
ed case, metabolic acidosis, severe base 
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deficit, leukocytosis, hypoglycaemia, 
increase in serum BUN, creatinine, ALP 
and triglyceride concentrations were de-
tected. The absence of haematological 
abnormalities, such as anaemia and pan-
cytopenia, is interpreted to be due to the 
acute period of toxicity (Table 1).
Appropriate symptomatic and 
supportive therapy is recommended 
for CPH toxicity. In the presence of 
hypotension, intravenous administration 
of noradrenaline or phenylephrine, 
balanced fluid therapy, control of 
hypothermia, oral administration of 
activated charcoal to prevent absorption 
of the drug, and use of diazepam or 
lorazepam for the treatment of seizures 
are important (Currance et al., 2005; 
AHFS Drug Info, 2010; FDA Label, 
2017). Due to the opposite effect and the 
risk of aspiration pneumonia, the use of 
emetic drugs should be avoided (FDA 
Label, 2017). In combination with CPH, 
acetaminophen, antacids, antidiarrheal 
mixtures, bromocriptine, buspiron, 
cabergoline, calcium channel blockers, 
central nervous system depressant 
agents, desmopressin, diazoxide, dipiron, 
dopamine, doxorubicin, epinephrine, 
laxatives, loop diuretics, opiates, drugs 
that cause prolonging in QT interval, 
tricyclic antidepressants or quinidine 
should be used with caution (AHFS Drug 
Info, 2010; Gollakner, 2019). Although 
it is still considered effective in dogs to 
stimulate decontamination and emesis 
with activated charcoal, its use in cats 
has decreased. For this reason, although 
the proper use of activated charcoal is 
beneficial, clinicians should evaluate the 
benefits and risks prior to its use (Means 
and Wismer, 2018). In the management of 
this case, since it has no specific antidote, 
treatment success was achieved with a 
symptomatic and supportive treatment 
protocol consisting of a combination of 
heat and oxygen support, fluid therapy, 
norepinephrine tartrate, furosemide and 
activated charcoal. 
Chlorpromazine toxicity, which is the 
subject of this case report, is presented 
for the first time based on the available 
information. The case was successfully 
treated with symptomatic and supportive 
treatment approaches, based on clinical 
and laboratory findings. In conclusion, 
it has been evaluated that in the 
management of chlorpromazine toxicity, 
continuous cardiac monitoring, control 
of heart frequency and rhythm, control of 
blood pressure and body temperature are 
very important, while the administration 
of IV fluids, norepinephrine, diuretic 
and activated charcoal contributed to the 
successful outcome. 
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Klorpromazin je derivat fenotiazina sa 
sedativnim učinkom, a rabi se za sprječavanje 
mučnine i povraćanja, posebice u slučajevima 
bolesti kretanja u mačaka. Pri velikim dozama 
ima ozbiljne nuspojave poput slabosti, 
drhtanja, gubitka tonusa analnog sfinktera i 
refleksa, hipotenzije, abnormalnosti srčanog 
ritma, kome, uznemirenosti i napadaja. U 
ovoj analizi slučaja, u četveromjesečnog 
mačića turske pasmine van težine 1,2 kg koji 
je doveden na hitnu pomoć Veterinarskog 
fakulteta Selcuk Sveučilišta s primjećenim 
simptomima stagnacije, drhtanja, povraćanja i 
prekomjerne pospanosti otkriveno je trovanje 
klorpromazinom. Kliničkim pregledom 
mačke utvrđena je hipotermija (35,2 °C), 
hiperpneja (88 udisaja/min), hipersalivacija, 
konstipacija, prekomjerna uznemirenost, 
drhtanje i nekoordinacija. Iz anamneze je 
otkriveno da je mačić prije puta oralno primio 
100 mg klorpromazina, za sprječavanje 
bolesti kretanja. Na elektrokardiografskom 
pregledu ustvrđena je sinusna tahikardija 
(220 otkucaja/min), povećanje amplitude P 
vala, podizanje ST segmenta i hipotenzija (S/
MAP/D = 148/124/112). Glavni laboratorijski 
nalazi bili su metabolička acidoza (pH 7,278), 
hipoglikemija (61 mg/dL), leukocitoza (22,43 
m/mm3), povećanje koncentracije ureje 
u krvi (17,7 mg/dL), kreatinina (0,6 mg/
dL) i ALP (121 U/L) i hipertrigliceridemija 
(122 mg/dL). Prema anamnezi, kliničkim, 
laboratorijskim i EKG nalazima, mačiću je 
dijagnosticirano trovanje prekomjernom 
dozom klorpromazina te je hospitaliziran, 
uz kontinuirano praćenje rada srca. Mačić 
je primao Ringerov laktat, norepinefrin 
tartrat, furosemid, aktivni ugljen i terapiju 
kisikom. Liječenje je bilo uspješno. Zaključno, 
procijenjeno je da su kontinuirano praćenje 
rada srca i kontrola hipotenzije bile važne 
u liječenju trovanja klorpromazinom te 
da tekuća terapija, norepinefrin, diuretik i 
aktivni ugljen postižu uspjeh u liječenju.
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